Pharmacogenetic Optimization of Smoking Cessation Treatment.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  TIPS - Trends in Pharmacological Sciences

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.tips.2016.09.006PMID 27712845PMCID PMC5195866
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brain Responses to Smoking Cues Differ Based on Nicotine Metabolism Rate.

  2016cited by this paper
• Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.

  2015cited by this paper
• Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation

  2015cited by this paper
• Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.

  2015cited by this paper
• Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism

  2015cited by this paper
• Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking

  2015cited by this paper
• A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism

  2015cited by this paper
• Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration

  2015cited by this paper
• Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers.

  2015cited by this paper
• Effect of the rs1051730-rs16969968 variant and smoking cessation treatment: a meta-analysis.

  2015cited by this paper
• CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis.

  2015influential reference
• Organic cation transporter variation and response to smoking cessation therapies.

  2014cited by this paper
• Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).

  2014influential reference
• Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes

  2014cited by this paper
• Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African American smokers

  2014cited by this paper
• Known and Novel Sources of Variability in the Nicotine Metabolite Ratio in a Large Sample of Treatment-Seeking Smokers

  2014cited by this paper
• Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

  2013cited by this paper
• CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers

  2013cited by this paper
• Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.

  2013cited by this paper
• 2031 – Analysis Of Nicotinic Receptor Genes In Nicotine Replacement Treatment

  2013cited by this paper
• Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes.

  2013cited by this paper
• The SLC22 family with transporters of organic cations, anions and zwitterions.

  2013cited by this paper
• The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence.

  2013cited by this paper
• Nicotinic acetylcholine receptor variation and response to smoking cessation therapies

  2013cited by this paper
• High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial.

  2013cited by this paper
• 2121 – Diffusion Tensor Imaging In Non-resistant Unipolar Major Depression: Preliminary Results

  2013cited by this paper
• CYP2B6 Non-Coding Variation Associated with Smoking Cessation Is Also Associated with Differences in Allelic Expression, Splicing, and Nicotine Metabolism Independent of Common Amino-Acid Changes

  2013cited by this paper
• Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI

  2012cited by this paper
• CYP2B6 and Bupropion's Smoking‐Cessation Pharmacology: The Role of Hydroxybupropion

  2012cited by this paper
• Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.

  2012influential reference
• Nicotine replacement therapy for smoking cessation.

  2012cited by this paper
• Rapid Nicotine Clearance is Associated with Greater Reward and Heart Rate Increases from Intravenous Nicotine

  2012cited by this paper
• Association Between Genetic Variants on Chromosome 15q25 Locus and Objective Measures of Tobacco Exposure

  2012cited by this paper
• Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials

  2011influential reference
• Habenular a5 nicotinic receptor subunit signalling controls nicotine intake

  2011cited by this paper
• Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.

  2011cited by this paper
• A nationwide analysis of US racial/ethnic disparities in smoking behaviors, smoking cessation, and cessation-related factors.

  2011cited by this paper
• CHRNA3 rs1051730 genotype and short-term smoking cessation.

  2011cited by this paper
• Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5‐A3‐B4) predict severity of nicotine addiction and response to smoking cessation therapy

  2011cited by this paper
• Habenular α5* nicotinic receptor signaling controls nicotine intake

  2011cited by this paper
• PharmGKB summary: very important pharmacogene information for CYP2B6

  2010cited by this paper
• The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19

  2010cited by this paper
• Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients.

  2010cited by this paper
• Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism

  2010cited by this paper
• Dopamine D4 Receptor Gene Variation Moderates the Efficacy of Bupropion for Smoking Cessation

  2010cited by this paper
• Common and Unique Biological Pathways Associated with Smoking Initiation/Progression, Nicotine Dependence, and Smoking Cessation

  2010cited by this paper
• Genome-wide meta-analyses identify multiple loci associated with smoking behavior

  2010cited by this paper
• The DRD4 receptor Exon 3 VNTR and 5′ SNP variants and mRNA expression in human post‐mortem brain tissue

  2010cited by this paper
• Genetic Variation in Nicotine Metabolism Predicts the Efficacy of Extended‐Duration Transdermal Nicotine Therapy

  2010cited by this paper
• Nicotine addiction.

  2010cited by this paper
• A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation

  2010cited by this paper
• Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study.

  2009cited by this paper
• Nicotine chemistry, metabolism, kinetics and biomarkers.

  2009cited by this paper
• Nicotinic acetylcholine receptor β2 subunit gene implicated in a systems-based candidate gene study of smoking cessation

  2008cited by this paper
• Variants in nicotinic receptors and risk for nicotine dependence.

  2008cited by this paper
• Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro–In Vivo Study

  2008influential reference
• Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch

  2008cited by this paper
• Nicotine replacement therapy for smoking cessation.

  2008cited by this paper
• Stability of the Nicotine Metabolite Ratio in ad Libitum and Reducing Smokers

  2008cited by this paper
• Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) Activity

  2008cited by this paper
• Toward Personalized Therapy for Smoking Cessation: A Randomized Placebo‐controlled Trial of Bupropion

  2008cited by this paper
• CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.

  2007cited by this paper
• Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.

  2007influential reference
• Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals

  2007influential reference
• Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro.

  2006cited by this paper
• Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate.

  2006cited by this paper
• Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation

  2006cited by this paper
• Genetic Architecture of Smoking Behavior: A Study of Finnish Adult Twins

  2006cited by this paper
• CYP2A6 genotype and the metabolism and disposition kinetics of nicotine

  2006cited by this paper
• METABOLISM AND DISPOSITION OF VARENICLINE, A SELECTIVE α4β2 ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, IN VIVO AND IN VITRO

  2006cited by this paper
• Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

  2005cited by this paper
• Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation

  2005cited by this paper
• Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity

  2004cited by this paper
• Smoking cessation by socioeconomic status and marital status: the contribution of smoking behavior and family background.

  2004cited by this paper
• Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

  2004cited by this paper
• The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour

  2004cited by this paper
• In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography.

  2003cited by this paper
• The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit

  2000cited by this paper
• Bupropion is a nicotinic antagonist.

  2000cited by this paper
• Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers

  1999cited by this paper
• Nicotine metabolism defect reduces smoking

  1998cited by this paper
• A comparison of sustained-release bupropion and placebo for smoking cessation.

  1997cited by this paper
• Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.

  1996cited by this paper
• Role of human cytochrome P4502A6 in C-oxidation of nicotine.

  1996cited by this paper
• Nicotine medications for smoking cessation.

  1995cited by this paper
• Gender differences in smoking cessation after 3 years in the Lung Health Study.

  1995cited by this paper

• Nicotinic acetylcholine receptors-targeting drug discovery.

  2026cites this paper
• A phenome-wide association study of genetically determined nicotine metabolism reveals novel links with health-related outcomes

  2025cites this paper
• Hydrogel Encapsulation of a Designed Fluorescent Protein Biosensor for Continuous Measurements of Sub-100 nM Nicotine.

  2025cites this paper
• Precision Medicine in Substance Use Disorders: Integrating Behavioral, Environmental, and Biological Insights.

  2025cites this paper
• Cognitive Distortions as Barriers to Seeking Smoking Cessation Treatment: A Comparative Study

  2024cites this paper
• Fine-mapping the CYP2A6 regional association with nicotine metabolism among African American smokers

  2024cites this paper
• The genetic landscape of substance use disorders

  2024cites this paper
• Nicotinic Receptor Alpha-5 Subunit Gene Polymorphism is Associated with Heavy Smoking Under a Range of Nicotine Dosing Conditions.

  2024cites this paper
• Individual variations in motives for nicotine self-administration in male rats: evidence in support for a precision psychopharmacology

  2024cites this paper
• Quantitation of Ten Urinary Nicotine Metabolites, Including 4-Hydroxy-4-(3-pyridyl) Butanoic Acid, a Product of Nicotine 2'-Oxidation, and CYP2A6 Activity in Japanese Americans, Native Hawaiians, and Whites.

  2023cites this paper
• Influence of CYP2A6 genetic variation, nicotine dependence severity, and treatment on smoking cessation success.

  2023cites this paper
• A Phenome-wide association study of a genetic score for the nicotine metabolite ratio

  2023cites this paper
• CYP2A6 activity and cigarette consumption interact in smoking-related lung cancer susceptibility.

  2023cites this paper
• The 2022 Ferno Award Address: CrEATE, An Efficient Crossover Evaluation of Addiction Treatment Efficacy.

  2022cites this paper
• NCI Monograph 23. Treating Smoking in Cancer Patients: An Essential Component of Cancer Care

  2022cites this paper
• Sex and Gender in lung diseases and sleep disorders: A state of the art review. Part 2.

  2022cites this paper
• Comparative Assessment of Outcomes in Drug Treatment for Smoking Cessation and Role of Genetic Polymorphisms of Human Nicotinic Acetylcholine Receptor Subunits

  2022cites this paper
• Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters

  2021cites this paper
• A genome-wide association study of nausea incidence in varenicline-treated cigarette smokers.

  2021cites this paper
• Impact Of Cyp2a6 Activity On Nicotine Reinforcement And Cue-Reactivity In Daily Smokers.

  2021cites this paper
• Biochemistry of nicotine metabolism and its relevance to lung cancer

  2021cites this paper
• The Role of Pharmacogenetics in Smoking

  2021cites this paper
• Addressing Smoking in Musculoskeletal Specialty Care

  2021cites this paper
• Behavioral and Genetic Factors Associated with Successful Long-Term Cessation in Persons with HIV Who Smoke Cigarettes

  2021cites this paper
• The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions

  2020cites this paper
• Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation

  2020cites this paper
• New Biological Insights into Smoking Cessation

  2020cites this paper
• Genetics of Smoking Behaviors in American Indians

  2020cites this paper
• Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo‐Controlled Trial

  2020cites this paper
• Summary and Future Applications of Precision Medicine in Pulmonary, Critical Care, and Sleep Medicine

  2020cites this paper
• Clinical Trials for Stimulant Use Disorders: Addressing Heterogeneities That May Undermine Treatment Outcomes.

  2020cites this paper
• Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent

  2020cites this paper
• Temperance, Moral Friendship, and Smoking Cessation.

  2019cites this paper
• Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline

  2019cites this paper
• Pharmacogenomics of chronic obstructive pulmonary disease

  2019cites this paper
• Toward the implementation of genomic applications for smoking cessation and smoking-related diseases.

  2018cites this paper
• Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment

  2018cites this paper
• Preparing the Way: Exploiting Genomic Medicine to Stop Smoking.

  2018cites this paper
• Cytochrome P450 in Pharmacogenetics: An Update.

  2018cites this paper
• Genome‐wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences

  2018cites this paper
• P450 Pharmacogenetics in Indigenous North American Populations

  2018cites this paper
• Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.

  2017cites this paper